
Kyntra Bio Inc (NASDAQ:KYNB – Free Report) – Equities research analysts at HC Wainwright lifted their FY2026 EPS estimates for shares of Kyntra Bio in a research note issued on Tuesday, November 17th. HC Wainwright analyst M. Keller now expects that the company will earn ($14.26) per share for the year, up from their previous estimate of ($17.61). HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for Kyntra Bio’s current full-year earnings is ($16.04) per share.
A number of other equities analysts also recently weighed in on KYNB. Lake Street Capital dropped their target price on shares of Kyntra Bio to $8.00 and set a “buy” rating for the company in a research note on Tuesday. Zacks Research upgraded Kyntra Bio from a “strong sell” rating to a “hold” rating in a report on Tuesday, November 10th. Maxim Group started coverage on Kyntra Bio in a research report on Tuesday, October 13th. They issued a “buy” rating and a $35.00 price objective for the company. Finally, Weiss Ratings lowered shares of Kyntra Bio from a “sell (d+)” rating to a “sell (d)” rating in a research note on Tuesday, November 10th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $25.20.
View Our Latest Stock Analysis on Kyntra Bio
Kyntra Bio Stock Down 6.2%
Kyntra Bio stock opened at $1.83 on Friday. The stock has a 50-day simple moving average of $5.36 and a 200 day simple moving average of $6.75. Kyntra Bio has a 12-month low of $1.78 and a 12-month high of $10.47.
Institutional Trading of Kyntra Bio
An institutional investor recently bought a new stake in Kyntra Bio stock. Renaissance Technologies LLC purchased a new position in shares of Kyntra Bio Inc (NASDAQ:KYNB – Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 27,481 shares of the company’s stock, valued at approximately $186,000. Renaissance Technologies LLC owned 0.68% of Kyntra Bio at the end of the most recent reporting period. 72.71% of the stock is currently owned by hedge funds and other institutional investors.
About Kyntra Bio
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
Featured Articles
- Five stocks we like better than Kyntra Bio
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Kyntra Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kyntra Bio and related companies with MarketBeat.com's FREE daily email newsletter.
